Gain Therapeutics' (GANX) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed a “Buy” rating on Gain Therapeutics and maintained an $8.00 price target, implying potential upside of 367.84% from the stock’s $1.71 price. The broader analyst consensus is “Moderate Buy,” with a $7.50 target.
• Gain Therapeutics reported quarterly EPS of -$0.11, beating analysts’ consensus estimate of -$0.14. Analysts expect a full-year EPS loss of approximately $0.50.
• The clinical-stage biotechnology company develops small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders using its proprietary SEE-Tx drug-discovery platform.

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright's price target points to a potential upside of 367.84% from the stock's current price.

Several other analysts also recently weighed in on the company. Weiss Ratings restated a "sell (e+)" rating on shares of Gain Therapeutics in a research report on Friday, September 4th. BTIG Research reissued a "buy" rating and set a $5.00 target price on shares of Gain Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded shares of Gain Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Sunday, June 21st. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $7.50.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.71 on Monday. Gain Therapeutics has a 1 year low of $1.53 and a 1 year high of $4.34. The company has a market capitalization of $74.62 million, a price-to-earnings ratio of -3.42 and a beta of 0.19. The business has a fifty day simple moving average of $1.83 and a two-hundred day simple moving average of $1.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.36 and a quick ratio of 4.36.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. Research analysts forecast that Gain Therapeutics will post -0.5 EPS for the current year.

Institutional Trading of Gain Therapeutics

Several institutional investors have recently modified their holdings of GANX. Apollon Wealth Management LLC raised its holdings in shares of Gain Therapeutics by 33.7% during the first quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company's stock valued at $51,000 after purchasing an additional 6,675 shares during the period. Two Sigma Securities LLC bought a new stake in Gain Therapeutics in the 2nd quarter worth approximately $26,000. HB Wealth Management LLC purchased a new stake in Gain Therapeutics in the 2nd quarter worth about $26,000. HighTower Advisors LLC purchased a new stake in shares of Gain Therapeutics during the 2nd quarter worth $35,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Gain Therapeutics during the second quarter valued at about $277,000. Institutional investors own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. The company's research is directed at restoring the function of misfolded or dysfunctional proteins that contribute to disease progression.

Gain Therapeutics uses its proprietary SEE-Tx drug-discovery platform to identify previously unrecognized allosteric binding sites on proteins and develop compounds designed to stabilize or reactivate those proteins.